Just because we need something to talk about that's not mega tech…
VRTX put in another strong quarter. 18% y/y revenue growth. GAAP income up 9%. Also with a slight raise to forward guidance. Also of note, they have $9.8 billion in cash and no debt. This puts them in an interesting position should a lot of start up biotech companies start running out of money.
Also interesting, they have 2 drugs in final testing stages, one for sickle cell disease and one one for pain. They have already hired staff to get these drugs quicky to market.
https://finance.yahoo.com/news/vertex-reports-third-quarter-2022-200100403.html
Full disclosure I own shares of VRTX and it's been a beast this year.
Leave a Reply